Hi all,
Thank you for your kind words.
Additional info I gathered yesterday + my opinion:
There was a potential investor who went there for Acrux (ACR) presentation but became attracted to Imugene because of its potential. He tried to place a dollar value on IMU SP, which was not unlike us, Few Pennies for example. Interestingly, but probably not significant, Leslie responded that she thought Imugene has the potential to reach $1. I can't recall whether she said this 'before she joined' or 'after she joined'.
Anyway, just like any other pennystock investment, there's always a significant risk - market doesn't tolerate failure & will punish severely, sometimes beyond the fundamental value of the company. The contrast between ACR & IMU current SP opened my eyes about this. ACR has a cash reserve of $32m but an MC of only $25m. On the other hand IMU with $11m but $100m MC.
The presenter of ACR presentation, Michael Kotsanis, said this was due to recent termination of a licensing agreement with their big pharma partner, Eli Lilly. Michael tried to promote ACR pipelines & potentials so it's difficult for him to explain how it's possible for a company to have an MC lower than the cash reserve. Maybe it's a good buying opportunities? But I'm really not into pennystock except IMU.
So, we have a massive potential on one hand if IMU is successful & a big fall on the other for undesirable results. Remember to always be responsible on your investment (I really should say this to myself everyday, shouldn't I?).
Take care!
Add to My Watchlist
What is My Watchlist?
